Brokerages Set Catalent Inc (NASDAQ:CTLT) PT at $28.67
Catalent Inc (NASDAQ:CTLT) has been given a consensus recommendation of “Hold” by the seven analysts that are currently covering the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $28.67.
A number of analysts have commented on the company. Jefferies Group restated a “hold” rating and issued a $28.00 price target (up previously from $25.00) on shares of Catalent in a research report on Thursday, September 29th. Morgan Stanley restated a “hold” rating on shares of Catalent in a research report on Tuesday, August 30th. Wells Fargo & Co. upgraded Catalent from a “market perform” rating to an “outperform” rating in a research report on Tuesday, June 21st. Zacks Investment Research upgraded Catalent from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $30.00 price target (down previously from $30.50) on shares of Catalent in a research report on Tuesday, August 30th.
In related news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the stock in a transaction dated Friday, September 9th. The stock was sold at an average price of $23.58, for a total transaction of $403,234,623.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Hedge funds have recently added to or reduced their stakes in the company. Pacer Advisors Inc. acquired a new stake in Catalent during the second quarter valued at about $102,000. Barclays PLC boosted its stake in Catalent by 406.7% in the second quarter. Barclays PLC now owns 5,275 shares of the company’s stock valued at $121,000 after buying an additional 4,234 shares in the last quarter. Emerald Acquisition Ltd. acquired a new stake in Catalent during the second quarter valued at about $123,000. LS Investment Advisors LLC boosted its stake in Catalent by 85.2% in the second quarter. LS Investment Advisors LLC now owns 7,131 shares of the company’s stock valued at $164,000 after buying an additional 3,280 shares in the last quarter. Finally, Tower Research Capital LLC TRC acquired a new stake in Catalent during the second quarter valued at about $196,000.
Shares of Catalent (NASDAQ:CTLT) opened at 25.98 on Tuesday. The company has a market cap of $3.24 billion and a P/E ratio of 29.19. Catalent has a 52-week low of $18.92 and a 52-week high of $32.24. The company has a 50-day moving average price of $25.34 and a 200-day moving average price of $25.68.
Catalent (NASDAQ:CTLT) last issued its quarterly earnings results on Monday, August 29th. The company reported $0.52 EPS for the quarter, missing analysts’ consensus estimates of $0.53 by $0.01. The business earned $532.20 million during the quarter. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.61 earnings per share. On average, equities analysts predict that Catalent will post $1.40 EPS for the current year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.